Rethinking HER2 Status: Practical Testing Considerations for HER2-Low and -Ultralow Advanced Breast Cancer

episode

CME in Minutes: Education in Oncology & Hematology not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

Transrapid, Flugtaxis, Hyperloop – Warum es neuartige Verkehrstechnik so schwer hat 28 min · 22 Sep 2026 · Das Wissen | SWR

5 On It & reacting to Bears locker room sound (Hour 3) 41 min · 21 Sep 2026 · Rahimi & Grote Show

Anthony Herron shares observations from Bears' ugly loss to Vikings (Hour 2) 41 min · 21 Sep 2026 · Rahimi & Grote Show

Caleb Williams exits with hamstring injury in Bears' 9-3 loss to Vikings (Hour 1) 37 min · 21 Sep 2026 · Rahimi & Grote Show

Bears reflect on their struggles in 9-3 loss to Vikings 11 min · 21 Sep 2026 · Rahimi & Grote Show

5 On It: Reacting to optimistic injury news on Caleb Williams 20 min · 21 Sep 2026 · Rahimi & Grote Show

Report any issue

Source

Recorded19 Feb 2026

Publisherc.answersincme.com ↗

Handlerec:16004729

Show notes

Please visit answersincme.com/CZS860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Giuseppe Curigliano, MD, PhD. In this activity, an expert in oncology discusses the differentiation of patients with HER2-low/ultralow/negative advanced breast cancer and treatment with antibody-drug conjugates. Upon completion of this activity, participants should be better able to: Differentiate HER2-low, -ultralow, and -negative advanced breast cancer; Identify patients with HER2-low and -ultralow advanced breast cancer who would benefit from treatment with antibody-drug conjugates; and Apply evidence-based strategies to connect testing to treatment in patients with HER2-low or -ultralow advanced breast cancer.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in